10-Q: AIXIN Life Reports Steep Revenue Decline, Mounting Losses

AIXIN Life International, Inc. reported a significant decrease in revenue and an increased net loss for the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue for the three months ended September 30, 2025, decreased by 68% to $301,979 from $936,406 in the prior year period.
• Total revenue for the nine months ended September 30, 2025, decreased by 63% to $1,161,739 from $3,120,615 in the prior year period.
• Net loss for the three months ended September 30, 2025, was $(340,461), a 38% decrease in loss compared to $(546,186) in the prior year.
• Net loss for the nine months ended September 30, 2025, increased by 7% to $(1,413,674) from $(1,326,569) in the prior year period.
• Cash and cash equivalents decreased from $62,310 at December 31, 2024, to $19,113 at September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(1,772,076), a significant increase from $(548,130) in the prior year period.
• The company reported a working capital deficit of $6,765,269 as of September 30, 2025.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to limited resources and deficiencies in internal control over financial reporting.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by steep revenue declines across all segments, increasing net losses over the nine-month period, a critical working capital deficit, and a substantial increase in cash used in operations. The 'going concern' warning and ineffective internal controls further underscore the precarious situation, outweighing any minor improvements in three-month net loss.

Positives

• Net loss for the three months ended September 30, 2025, decreased by 38% to $(340,461) compared to $(546,186) in the same period of 2024, primarily due to decreased operating costs and expenses.
• Non-operating income for the nine months ended September 30, 2025, increased to $427,698, largely due to a gain from forgiveness of other payable of $465,586.

Negatives

• Total revenue for the three months ended September 30, 2025, decreased by 68% to $301,979, with all segments experiencing significant declines (Direct Sales -87%, Pharmacies -94%, Hotel -29%, Manufacture and Sale -64%).
• Total revenue for the nine months ended September 30, 2025, decreased by 63% to $1,161,739, with all segments showing substantial declines (Direct Sales -89%, Pharmacies -90%, Hotel -29%, Manufacture and Sale -46%).
• Net loss for the nine months ended September 30, 2025, increased by 7% to $(1,413,674).
• Cash and cash equivalents significantly decreased from $62,310 at December 31, 2024, to $19,113 at September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, increased substantially to $(1,772,076) from $(548,130) in the prior year period.
• The company has a working capital deficit of $6,765,269 as of September 30, 2025.
• Cost of sales as a percentage of sales increased for the Pharmacy segment (70% in Q3 2025 vs. 27% in Q3 2024; 67% in 9M 2025 vs. 29% in 9M 2024) and Manufacture and Sale segment (101% in Q3 2025 vs. 76% in Q3 2024; 101% in 9M 2025 vs. 71% in 9M 2024), indicating reduced profitability per sale.
• The company returned $655,740 of a government grant for the nine months ended September 30, 2025, due to not receiving the full promised amount.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses, increased cash used in operating activities, and a significant working capital deficit.
• The company's liquidity plan, which includes cost reductions, sales of higher margin products, and raising cash through related party loans and potential equity offerings, has no assurance of successful implementation.
• Operations in the PRC are subject to political, economic, and legal environment risks, including changes in governmental policies, anti-inflationary measures, currency conversion, and taxation.
• The RMB is not freely convertible into foreign currencies, which may affect remittances.
• The company faces concentration of credit risk with one customer accounting for 38% and 43% of total revenue for the three and nine months ended September 30, 2025, respectively.
• Reliance on a few major suppliers (e.g., Supplier A and D accounted for 31% and 17% of purchases in Q3 2025, and 30% and 11% in 9M 2025) creates supplier concentration risk.
• The company's revenue model is new and evolving, and there is no certainty it will be successful or achieve sustained profitability.
• Future operating results depend on demand for products, level of competition, and management's ability to manage business and growth.
• Additional issuances of equity or convertible debt securities will result in dilution to current shareholders and could decrease common stock price.
• Additional financing may not be available on acceptable terms or at all, potentially restricting business operations.
• The company is subject to substantial risks inherent in developing a new business enterprise within extremely competitive industries.
• Operating losses are anticipated until a substantial and stable revenue base is developed.
• Results of operations may be affected by inflation, particularly rising prices for products and operating costs if increases cannot be passed to customers.
• Global events such as pandemics, the war in Ukraine, the conflict in Palestine, shifts in international alliances, and tariffs may adversely impact capital markets and the company's ability to raise funds.

Future Outlook

The company intends to seek additional opportunities in China's growing healthcare market, including expanding its product line through internal research and acquisitions, acquiring more pharmacies and retail outlets, and potentially operating nursing homes and clinics. Management believes its liquidity plan, which includes continuous cost reductions, sales of higher margin products, and raising cash through related party loans and potential equity offerings, should provide sufficient liquidity for the next twelve months, though there is no assurance of successful implementation.

Management Comments

• Management believes that it has developed a liquidity plan that, if executed successfully, should provide sufficient liquidity to meet its obligations as they become due for a reasonable period of time, and allow the development of its core business.
• The plan includes gaining positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products.
• The plan also includes raising cash through loans from related parties and potential equity offerings.
• Management believes the competitive strengths that will enable growth include the ability to design and manufacture products responsive to consumer needs and a coordinated omni-channel distribution network.
• Our ability to operate profitably and generate positive cash flow will be determined by our ability to attract a large and loyal customer base and provide the information and products they need cost effectively.

Industry Context

The company operates in the health and wellness market in China, targeting the growing middle class with nutritional products and wellness supplements. The reported declines across all segments, including pharmacies and direct sales, suggest that the company is struggling to capitalize on this growth, possibly due to intense competition, economic downturns, and the shift towards online shopping. The hotel segment also suffered from the economic downturn and slowdown in the catering industry. The strategy to become vertically integrated and offer a diversified omni-channel model is aligned with broader industry trends but has not yet translated into positive financial results.

Comparison to Industry Standards

• The significant revenue declines (63-68%) across all business segments are substantially worse than typical growth rates for established health and wellness companies in a growing market like China, which often see single to double-digit percentage growth.
• A working capital deficit of $6.77 million and a cash balance of $19,113 are indicative of severe liquidity issues, far below healthy industry benchmarks for operational stability and growth.
• The increase in net cash used in operating activities to $(1.77) million for nine months, compared to $(0.55) million in the prior year, suggests a deteriorating operational efficiency and cash burn rate that is unsustainable compared to industry peers.
• The increase in cost of sales as a percentage of revenue for pharmacy (70% vs 27%) and manufacturing (101% vs 71%) segments indicates a significant erosion of gross margins, which is highly unfavorable compared to industry standards where gross margins for health products and retail typically range from 30-60% or higher.
• The disclosure of 'not effective' internal controls is a serious governance issue, placing the company significantly below the standards expected of publicly traded entities, especially compared to well-governed companies like Alibaba Health Information Technology or JD Health International in the Chinese healthcare e-commerce space, or major pharmacy chains globally.

Corporate Governance

Related Party Transactions

• Accounts receivable from related parties totaled $430,672 as of September 30, 2025, primarily from entities controlled by Mr. Quanzhong Lin (Chairman, CEO, major shareholder) and Huiliang Jiao (Director).
• Sales revenue to related parties for the three months ended September 30, 2025, was $196,453, and for the nine months was $582,391, primarily to entities controlled by Mr. Lin and Mr. Jiao.
• Purchases from related parties for the three months ended September 30, 2025, were $5,350, and for the nine months were $31,068, primarily from entities controlled by Mr. Lin.
• Accounts payable to related parties totaled $50,097 as of September 30, 2025, primarily to entities controlled by Mr. Lin and Mr. Jiao.
• Advances to suppliers related parties totaled $11,765 as of September 30, 2025, from entities controlled by Mr. Lin.
• Unearned revenue related party consisted of $130,271 advance payment from Shengcaofeng Health Industry (Yunnan) Co., Ltd, owned by Huiliang Jiao.
• Due from related parties totaled $57,247 as of September 30, 2025, including amounts from entities controlled by Mr. Lin and Mianyang Aixin Cunshan Pharmacy.
• Due to related parties totaled $5,464,528 as of September 30, 2025, with $5,012,943 owed to Mr. Quanzhong Lin and $281,257 owed to Huiliang Jiao, indicating significant reliance on insider financing for working capital.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity offerings and a substantial risk of further share price depreciation due to poor financial performance and going concern issues.
• Creditors, particularly related parties, are exposed to increased risk given the company's working capital deficit and reliance on their continued support.
• Employees may face job insecurity or reduced compensation given the company's focus on cost reductions and overall financial struggles.
• Customers and suppliers may experience disruptions if the company's liquidity issues worsen or if its business operations are significantly curtailed.

Next Steps

• Implement the liquidity plan, focusing on continuous cost reductions and sales of higher margin products.
• Pursue financing arrangements, including loans from related parties and potential equity offerings.
• Address and remediate the identified material weaknesses in disclosure controls and internal control over financial reporting.
• Explore additional opportunities in the growing healthcare market in China, including expanding product lines and acquiring complementary businesses.
• Continue to monitor and manage risks associated with the political, economic, and legal environments in the PRC, as well as global events.

Key Dates

Recommendation

The company's financial health is in severe decline, marked by drastic revenue drops across all segments, persistent and increasing net losses over the nine-month period, and a critical working capital deficit. Cash reserves are minimal, and the rate of cash burn from operations has significantly accelerated. The explicit 'going concern' warning, coupled with acknowledged material weaknesses in internal controls, indicates fundamental operational and governance issues. While management outlines a liquidity plan, its success is highly uncertain. The heavy reliance on related party financing and the deteriorating profitability metrics suggest a high risk of further financial deterioration and potential insolvency. Investors should consider divesting immediately to avoid further capital loss.

Keywords

Health and Wellness, Nutritional Products, Pharmacies, Hotel Management, Manufacturing, China Market, SEC Filing, 10-Q, Financial Performance, Going Concern, Revenue Decline, Net Loss, Working Capital Deficit, Related Party Transactions, Internal Controls, OTC Markets